The Question I Get Every Week

Patients come in having already read the clinical trial abstracts. They know tirzepatide produced greater mean weight loss in SURMOUNT-1. They want to know which one I would choose for them — not in the abstract, but right now, given their insurance, their history, their body. That is a harder question than any trial can answer, and the answer changes depending on factors the trials were not designed to capture.

I have been prescribing GLP-1 receptor agonists since exenatide, and I started using semaglutide in clinical practice well before the STEP trials finished enrolling. Tirzepatide adds a GIP agonist arm to the mechanism, and that dual action genuinely matters — but not in the way most patients expect, and not for every patient.

What the Efficacy Difference Actually Looks Like in Practice

On paper, SURMOUNT-1 showed mean weight loss around 20–22% at the highest tirzepatide dose versus roughly 15% with semaglutide 2.4 mg in STEP-1. That gap is real, but it is a population average. In my practice I have patients on semaglutide who have lost 22% of body weight and patients on tirzepatide who plateaued at 10%. The trials tell you where the center of the distribution lands; they do not tell you where any individual will land.

What I tell patients is this: the ceiling is higher with tirzepatide, and for patients who need to lose 25% or more of body weight to meaningfully change their metabolic trajectory — advanced fatty liver disease, class III obesity with joint disease — that ceiling matters. For someone who needs to lose 15%, both drugs can get them there, and the choice should be made on other grounds.

Insurance and Formulary: The Constraint That Drives Most Decisions

I will be direct: for the majority of my patients, the choice between these two drugs is not a clinical decision at all. It is a formulary decision. Ozempic and Wegovy (semaglutide) have been on the market longer and have better formulary positioning at many commercial plans. Some employers have explicitly excluded tirzepatide for weight management while covering semaglutide. Others have done the reverse.

Before I even discuss mechanism with a patient, my MA runs a benefits check. If one drug has a $25 copay and the other requires a $650 out-of-pocket monthly spend, the conversation is short. Adherence over 12 to 18 months — which is what produces durable results — depends on affordability. The best drug the patient cannot keep filling is not the best drug.

Where prior authorization is required for both, I default to the drug I think gives the patient the better risk-benefit profile. But prior auth for tirzepatide for obesity (rather than diabetes) is still inconsistently granted in many payer systems, and I spend meaningful clinical time fighting those denials.

Patient Factors That Tip My Decision

When formulary is neutral, I start with comorbidities. Tirzepatide has demonstrated cardiovascular outcome data through SURPASS-CVOT, and the SELECT trial has now established semaglutide’s cardiovascular benefit in non-diabetic patients with established CVD. If a patient has had a myocardial infarction or stroke, semaglutide’s SELECT data is directly applicable and I weigh that heavily.

Gastrointestinal tolerance is the other major factor. The nausea profile of both drugs follows a similar titration-dependent pattern, but I find — and this is clinical impression, not trial data — that some patients who could not tolerate semaglutide above 1 mg manage tirzepatide at 10 mg without issue. The reverse also happens. I do not present either drug as the gentler option; I tell patients the GI side-effect profile is individual and we will titrate accordingly.

For patients with type 2 diabetes, the A1c trajectory matters alongside the weight trajectory. Tirzepatide’s glycemic efficacy in SURPASS is robust, and for patients who need both meaningful A1c reduction and significant weight loss, it is often my first choice. For patients with well-controlled diabetes who mainly need weight reduction, I am more likely to let formulary decide.

I also consider pen device ergonomics — the Ozempic and Wegovy pens remain somewhat more familiar to patients and pharmacists at this point, which reduces dosing errors in my older patient population.

When a Patient Switches — and What to Expect

Switching from semaglutide to tirzepatide is more common in my practice than the reverse, usually because a patient has plateaued after 9 to 12 months and we are trying to reach a higher dose ceiling. I restart at tirzepatide 2.5 mg regardless of what semaglutide dose they were on. The mechanisms overlap but are not identical, and I have seen enough nausea recurrence in patients who pushed directly to 5 or 7.5 mg to make cautious re-titration my standard approach.

The plateau question itself deserves attention. A patient who has lost 10% on semaglutide 1 mg and feels they have stalled has two options: escalate the dose if they are not yet at maximum, or switch. I exhaust the dose range first. Moving to tirzepatide prematurely, before a patient has been on the maximum tolerated semaglutide dose for at least 12 weeks, makes it impossible to know whether the plateau was drug-specific or dose-specific.

Switching in the other direction — from tirzepatide to semaglutide — usually happens because of insurance changes. Patients are understandably frustrated, and I am honest with them: some will maintain their results, some will see modest regain. We watch the weight trend closely for the first three months after transition.

What I Actually Say in the Room

The conversation I have with patients sounds something like this: both drugs work by reducing appetite and slowing gastric emptying; tirzepatide adds a second hormonal signal that on average produces modestly better weight loss at the population level; your individual response may differ from the average; insurance will shape the initial choice; and whichever drug we start, we will titrate slowly and adjust based on what your body does. We are not locked in.

That last part matters. Patients come in wanting a definitive answer, and I understand why. But obesity medicine does not work like a single-antibiotic-for-a-known-organism model. We have two good drugs with meaningfully different mechanisms, overlapping but distinct trial populations, and a payer environment that still treats obesity pharmacotherapy as optional. The clinical decision lives inside all of that — not above it.

Dr. Humberto Fernandez Miro, MD, is a board-certified physician and medical contributor at WeightLossPills.com, where he specializes in obesity medicine, GLP-1 therapy, and metabolic health.